What this means
This review summarizes earlier work on NAD+, a chemical that helps cells make energy. Its levels fall with age and are lower in the brains of people with Parkinson's.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of earlier studies, including animal and early human studies
- Kind of research
- A summary of earlier studies
The science
- Original title
- NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.
- Authors
- Wang T, Zhou X, Chen X
- Journal
- Frontiers in neurology
- Published
- Oct 15, 2026
- Study type
- Review · in humans
- PMID
- 42877680 ↗
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide, characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accumulation of α-synuclein (α-syn), mitochondrial dysfunction, and neuroinflammation. Nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme involved in cellular energy metabolism, DNA repair, and epigenetic regulation, declines with aging and is markedly reduced in the brains of patients with PD. Emerging evidence suggests that supplementation with NAD+ precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), exerts neuroprotective effects through multiple mechanisms, such as activation of the mitochondrial unfolded protein response (UPR∧mt), enhancement of autophagy, and suppression of excessive poly(ADP-ribose) polymerase 1 (PARP1) activation. This review summarizes the central role of NAD+ dysregulation in the pathogenesis of PD, with particular emphasis on the interplay between NAD+ depletion, mitochondrial quality control, proteostasis, and neuroinflammation. Furthermore, we discuss recent advances in NAD+-boosting strategies in PD models and clinical studies, highlighting their potential therapeutic implications for PD intervention.
Wang T, Zhou X, Chen X NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives. Frontiers in neurology. 2026. doi:10.3389/fneur.2026.1943801. PMID: 42877680. https://pubmed.ncbi.nlm.nih.gov/42877680/
Related research
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes.
Degenerative musculoskeletal disorders, including osteoarthritis (OA), intervertebral disc degeneration (IVDD), and osteoporosis (OP), are increasingly viewed as disorders of mitochondrial quality control (MQC) rather…
Targeting of Protein Persulfidation in Aging and Age-Related Disorders.
Aging is associated with a progressive loss of proteostasis and increased susceptibility to neurodegenerative and metabolic disorders.
Eye supplements that target aging pathways: a review of current evidence
This review looked at vitamins and similar products for eye diseases tied to aging. It says early signs look promising, but long-term benefit is not yet proven.
SIRT1-Redox Crosstalk in Aging: Adaptive Capacity and Cellular State Transitions.
Aging gradually reduces the ability of cells to maintain and restore homeostasis under metabolic and oxidative stress.
Nicotinamide Mononucleotide-Producing Probiotic Strain B12-N Attenuates Aging and Cognitive Decline in a Caenorhabditis elegans Model of Alzheimer's Disease:…
Nicotinamide mononucleotide (NMN) is an active component found in probiotics that may help alleviate Alzheimer's disease and the effects of aging.
See all research on NAD+ boosters →